NDA 021336 · Somerset
Emsam
Selegiline · Transdermal · Monoamine Oxidase Inhibitor; Monoamine Oxidase Type B Inhibitor
Last checked: Nov 20, 2026Latest source record: Jul 14, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Feb 27, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
34
3 Phase 3, 0 recruiting
FAERS reports
2,999
1,411 serious, 174 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . EMSAM is contraindicated in patients less than 12 years of age because of an increased risk of hypertensive crisis [see Contraindications (4) and Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). • EMSAM is...
What it is approved for
From the label in effect May 15, 2020.
EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . EMSAM ® (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD) ( 1 ).
Mechanism: The mechanism of action of selegiline (the drug substance of EMSAM) as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 10, 2014 Supplement 10 · Efficacy Pediatric Medical ReviewPediatric Medical ReviewPediatric Medical Secondary Review
- Feb 27, 2006 Original approval · Type 3 - New Dosage Form ReviewOther Important Information from FDALetter
3 products under this application
- EMSAM · SELEGILINE 9MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
- EMSAM · SELEGILINE 12MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
- EMSAM · SELEGILINE 6MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Selegiline" as an intervention, any sponsor and status, largest first.
- Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major DepressionPivotal-lookingCompleted
Somerset PharmaceuticalsIndustry
NCT00531947 · 308 participants · Start Jul 2007 · Primary completion Oct 2010
Drug: Selegiline Transdermal System; Placebo · For: Major Depressive Disorder
Sites: Dothan, Alabama; National City, California; San Diego, California · 20 sites in all
- Evaluation of Adhesion and Dermal Tolerability of EMSAMPivotal-lookingCompleted
Somerset PharmaceuticalsIndustry
NCT00531596 · 300 participants · Start Apr 2007
Drug: EMSAM (Selegiline Transdermal System) 6mg/24Hr; EMSAM (Selegiline Transdermal System) 9mg/24Hr and 1 more · For: Healthy
Sites: Scottsdale, Arizona; St. Petersburg, Florida
- Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major DepressionPivotal-lookingCompleted
Somerset PharmaceuticalsIndustry
NCT00285766 · 300 participants · Start Aug 2002
Drug: Selegiline Transdermal System · For: Major Depression
Sites: Chula Vista, California; San Diego, California; Upland, California · 15 sites in all
- Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1Pivotal-lookingCompleted
National Institute on Drug Abuse (NIDA)NIH
NCT00032929 · 269 participants · Start Mar 2001 · Primary completion Dec 2002
Drug: Selegiline · For: Cocaine-Related Disorders
Sites: Tucson, Arizona; Berkeley, California; Los Angeles, California · 16 sites in all
- Selegiline for Smoking Cessation - 1Pivotal-lookingCompleted
National Institute on Drug Abuse (NIDA)NIH
NCT00439413 · 246 participants · Start Jun 2007 · Primary completion Aug 2008
Drug: Selegiline Transdermal Patch; Placebo · For: Nicotine Dependence
Sites: College Park, Maryland; New Brunswick, New Jersey; Cincinnati, Ohio · 4 sites in all
- Selegiline Patch for Treatment of Nicotine DependencePivotal-lookingCompleted
Stanford UniversityAcademic, hospital or other
NCT01330030 · 243 participants · Start Jul 2005 · Primary completion Aug 2008
Drug: Selegiline · For: Tobacco Use Disorder
Sites: Stanford, California
- A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy SubjectsPivotal-lookingCompleted
Corium Innovations, Inc.Industry
NCT07452692 · 232 participants · Start Aug 23, 2026 · Primary completion Sep 26, 2026
Drug: Selegiline Transdermal Delivery System · For: Major Depressive Disorder (MDD)
Sites: Elin Pelin, Bulgaria; Sofia, Bulgaria · 3 sites in all
- Dopaminergic Mechanism of Memory Impairment in Parkinson's DiseasePivotal-lookingStatus unknown
Peking University Third HospitalAcademic, hospital or other
NCT04968613 · 150 participants (planned) · Start Jan 1, 2018 · Primary completion Dec 31, 2021
Drug: Madopar monotherapy; senfrol monotherapy and 1 more · For: Parkinson Disease; Memory Impairment
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective329
- insomnia189
- application site erythema183
- hallucination171
- dizziness170
- fall147
- dyskinesia140
- drug interaction135
- anxiety128
- depression128
- application site rash127
- tremor121
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 35 |
| 2007 | 311 |
| 2008 | 27 |
| 2009 | 43 |
| 2010 | 34 |
| 2011 | 203 |
| 2012 | 182 |
| 2013 | 145 |
| 2014 | 51 |
| 2015 | 199 |
| 2016 | 194 |
| 2017 | 224 |
| 2018 | 174 |
| 2019 | 195 |
| 2020 | 193 |
| 2021 | 165 |
| 2022 | 129 |
| 2023 | 147 |
| 2024 | 112 |
| 2025 | 132 |
| 2026 | 100 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Emsam (Selegiline)
2024 spending
$12.5M
Beneficiaries
866
5,355 claims
Per beneficiary
$14,487
$71.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,786,120 |
| 2021 | $12,367,030 |
| 2022 | $11,918,838 |
| 2023 | $12,397,890 |
| 2024 | $12,546,115 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis.
Larsen AJ, Teobaldi G, Espinoza Jeraldo RI, et al. · BMJ Ment Health 2025 · Systematic Review, Meta-Analysis
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.
Agnieszka W, Pawe P, Magorzata K · Curr Neuropharmacol 2022 · Systematic Review
- Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).
Nagler EV, Webster AC, Vanholder R, et al. · Nephrol Dial Transplant 2012 · Systematic Review
- Antidepressants for smoking cessation.
Hughes JR, Stead LF, Lancaster T · Cochrane Database Syst Rev 2003 · Meta-Analysis, Systematic Review
Sponsor: Somerset
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.